ANATARA LIFESCIENCES LTD 
"Anatara Lifesciences is striking a blow against antibiotic resistance."
A Good Gut Feeling
Anatara Lifesciences is nearing the market with its first product, called Detach, a treatment for production animals such as cattle and pigs designed to reduce gastrointestinal disorders in these animals, thereby increasing meat yield. Anatara filed for Australian approval of Detach in October 2016 and expects to be selling the product commercially to pig farmers in 2017. We see significant upside for Anatara from an option granted last year to the animal health major Zoetis over a worldwide license for Detach's use in production animals.
Anatara has argued that Detach's mechanism of action, which doesn't involve killing pathogens directly, makes the product one potential solution to the emerging problem of antibiotic resistance. Anatara is currently looking at human applications for Detach, where the market opportunity in Inflammatory Bowel Disease and other gastrointestinal diseases in need of new anti-inflammatory approaches is significant. We value Anatara at $2.22 base case and $5.94 optimistic case using a DCF approach. Our target price of $4.00 sits at around the midpoint of our valuation range.
To view the full research report, please visit:
http://abnnewswire.net/lnk/A6HH6134
About Anatara Lifesciences Ltd:
Anatara Lifesciences (ASX:ANR) is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach(TM) is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called "super bugs" that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.
Source:
Anatara Lifesciences Ltd
Contact:
Investor and Media inquiries: Dr Mel Bridges Chairman, Anatara Lifesciences Phone: +61-413-051-600 Email: melbridges@parmacorp.com Media: Jane Lowe IR department Phone: +61-411-117-774 Email: jane.lowe@irdepartment.com.au
